<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01126112</url>
  </required_header>
  <id_info>
    <org_study_id>TTD-09-03</org_study_id>
    <secondary_id>2009-016661-28</secondary_id>
    <nct_id>NCT01126112</nct_id>
  </id_info>
  <brief_title>Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer</brief_title>
  <acronym>FRAIL</acronym>
  <official_title>Phase II Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of first-line single-agent
      panitumumab in frail elderly patients with advanced Wild Type K-RAS colorectal cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of first-line single-agent
      panitumumab in frail elderly patients with advanced Wild Type K-RAS colorectal cancer
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival rate at 6 months</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of stable disease</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in patient-reported outcomes</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of molecular predictive markers for response.</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panitumumab: 6 mg/Kg Q2W Treatment cycles repeated every 14 days. Subjects will be evaluated for tumour response every 3 cycles (6 wks ± 1 wk) the first 24 weeks and every 8 weeks ± 2 weeks thereafter (per the revised-RECIST 1.1 guideline) until PD or withdrawal from the trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>Panitumumab: 6 mg/Kg Q2W</description>
    <arm_group_label>Panitumumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Inform Consent

          -  Age &gt; 70 years.

          -  Histologically documented metastatic colorectal cancer not candidate for surgical
             resection

          -  Wild type K-RAS

          -  Measurable disease by RECIST Criteria

          -  Intermediate or High-risk group according to the Köhne Prognostic Classification

          -  ECOG status &lt; 3

          -  Magnesium ≥ institutional lower limit of normal

          -  frail elderly patients and or not candidates for chemotherapy:

        Frail elderly patients: Presence of one or more of the following criteria:

          -  Dependence for one of the basic daily living activities (Katz Index)

          -  Three or more comorbid conditions according Charlson scale and dependence for one of
             the instrumental activities of daily living (IADL)

          -  Presence one or more of the following geriatric syndromes (age &gt; 85 years, fecal or
             urinary incontinence in the absence of stress, frequent falls, spontaneous bone
             fractures, neglect)

        Presence of one or more of the following criteria that make patients not candidates for
        chemotherapy:

          -  neutrophils &lt; 2000/mm3

          -  platelets &lt; 100.000/mm3

          -  creatinine clearance &lt; 30 ml/min and bilirubin levels &gt; 1.5 x ULN

          -  creatinine clearance &lt; 30 ml/min and AST or ALT levels &gt; 3 x UNL (if liver metastasis
             &gt; 5 x ULN)

        Exclusion Criteria:

          -  Patients will be excluded from the study if they have received prior systemic therapy
             for the treatment of metastatic colorectal carcinoma or antiEGFR therapy, with the
             exception of adjuvant fluoropyrimidine-based chemotherapy given at least six months
             prior to enrolment or oxaliplatin at least 12 months prior to enrolment.

          -  Systemic chemotherapy, hormonal therapy, immunotherapy or experimental or approved
             proteins/antibodies (eg, bevacizumab) ≤ 30 days before inclusion

          -  Unresolved toxicities from prior systemic therapy that, in the opinion of the
             investigator, does not qualify the patient for inclusion

          -  Patients cognitively impaired or with severe depression according mini mental state
             examination and geriatric depression scale.

          -  Patients with central nervous system metastases, or those with significant
             cardiovascular disease, will also be excluded.

          -  History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial
             pneumonitis or pulmonary fibrosis on baseline chest CT scan

          -  Treatment for systemic infection within 14 days before initiating study treatment

          -  Radiotherapy &lt; 14 days prior to inclusion in the study.

          -  Active inflammatory bowel disease or other bowel disease causing chronic diarrhoea
             (defined as &gt; 4 loose stools per day)

          -  History of any medical condition that may increase the risks associated with study
             participation or may interfere with the interpretation of the study results

          -  Known positive test for human immunodeficiency virus infection, hepatitis C virus,
             chronic active hepatitis B infection

          -  subject allergic to the ingredients of the study medication or to Staphylococcus
             protein A

          -  Any co-morbid disease that would increase risk of toxicity

          -  Any investigational agent within 30 days before enrolment

          -  Must not have had a major surgical procedure within 28 days of enrolment

          -  Subject unwilling or unable to comply with study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Sastre</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Clínico San Carlos. Madrid. Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish Cooperative Group for Gastrointestinal Tumour Therapy</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.ttdgroup.org</url>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2010</study_first_submitted>
  <study_first_submitted_qc>May 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2010</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced colorectal cancer; K-RAS; panitumumab</keyword>
  <keyword>advanced Wild Type K-RAS colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

